AstraZeneca PLC (AZNCF)
150.16
+3.90
(+2.67%)
USD |
OTCM |
Apr 30, 10:37
AstraZeneca Price to Book Value: 6.216 for April 30, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 29, 2024 | 6.055 |
| April 26, 2024 | 6.007 |
| April 25, 2024 | 6.047 |
| April 24, 2024 | 5.604 |
| April 23, 2024 | 5.808 |
| April 22, 2024 | 5.743 |
| April 19, 2024 | 5.639 |
| April 18, 2024 | 5.723 |
| April 17, 2024 | 5.802 |
| April 16, 2024 | 5.602 |
| April 15, 2024 | 5.628 |
| April 12, 2024 | 5.750 |
| April 11, 2024 | 5.651 |
| April 10, 2024 | 5.641 |
| April 09, 2024 | 5.579 |
| April 08, 2024 | 5.657 |
| April 05, 2024 | 5.515 |
| April 04, 2024 | 5.686 |
| April 03, 2024 | 5.455 |
| April 02, 2024 | 5.451 |
| April 01, 2024 | 5.622 |
| March 31, 2024 | |
| March 28, 2024 | 5.424 |
| March 27, 2024 | 5.335 |
| March 26, 2024 | 5.170 |
| Date | Value |
|---|---|
| March 25, 2024 | 5.276 |
| March 22, 2024 | 5.242 |
| March 21, 2024 | 5.188 |
| March 20, 2024 | 5.188 |
| March 19, 2024 | 5.146 |
| March 18, 2024 | 5.184 |
| March 15, 2024 | 5.205 |
| March 14, 2024 | 5.312 |
| March 13, 2024 | 5.402 |
| March 12, 2024 | 5.28 |
| March 11, 2024 | 5.282 |
| March 08, 2024 | 5.193 |
| March 07, 2024 | 5.119 |
| March 06, 2024 | 5.105 |
| March 05, 2024 | 4.990 |
| March 04, 2024 | 5.135 |
| March 01, 2024 | 5.148 |
| February 29, 2024 | 5.015 |
| February 28, 2024 | 5.188 |
| February 27, 2024 | 5.188 |
| February 26, 2024 | 5.148 |
| February 23, 2024 | 5.115 |
| February 22, 2024 | 5.009 |
| February 21, 2024 | 5.030 |
| February 20, 2024 | 5.089 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
4.182
Minimum
Dec 13 2021
13.56
Maximum
May 21 2020
7.786
Average
6.442
Median
Price to Book Value Benchmarks
| GSK PLC | 5.038 |
| Adaptimmune Therapeutics PLC | 7.402 |
| Biodexa Pharmaceuticals Plc | 0.9124 |
| Verona Pharma PLC | 5.048 |
Price to Book Value Related Metrics
| PE Ratio | 36.89 |
| PS Ratio | 4.926 |
| PEG Ratio | 1.061 |
| Price to Free Cash Flow | 40.54 |
| Price | 150.16 |
| Earnings Yield | 2.71% |
| Market Cap | 232.77B |
| PEGY Ratio | 1.004 |
| Operating PE Ratio | 24.61 |
| Normalized PE Ratio | 33.76 |